The Dow, S&P 500, and Nasdaq rally Wednesday as the stock market digests the latest CPI inflation report and earnings from several big U.S. banks.

The weight-loss succession race is heating up. Here's how biopharma execs talked up those efforts at JPM this week.

In a live taping of "The Readout LOUD" at #JPM25, Eli Lilly CEO Dave Ricks talks Trump, Medicare's drug price negotiation, ...

Eli Lilly CEO said he believed the company could find “significant common cause” with the Trump administration, even if there ...

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

SEC sues Elon Musk over Twitter purchase, Microsoft says businesses should get quantum ready in 2025, and more news to start ...

Ozempic, Wegovy or Mounjaro? The battle of the weight-loss injections - As drugs emerge as vital to the Government’s ...

Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...